Published: Guidance, quality standards and advice
Showing 1 to 2 of 2
| Title | Reference number | Published | Last updated |
|---|---|---|---|
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | ||
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 |